RU2223760C2 - Способы профилактики и лечения, применение усилителей чувствительности к инсулину - Google Patents
Способы профилактики и лечения, применение усилителей чувствительности к инсулину Download PDFInfo
- Publication number
- RU2223760C2 RU2223760C2 RU2002104459/14K RU2002104459K RU2223760C2 RU 2223760 C2 RU2223760 C2 RU 2223760C2 RU 2002104459/14 K RU2002104459/14 K RU 2002104459/14K RU 2002104459 K RU2002104459 K RU 2002104459K RU 2223760 C2 RU2223760 C2 RU 2223760C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- formula
- enhancer
- inhibitor
- mammal
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Изобретение относится к медицине, в честности к эндокринологии, и касается лечения сахарного диабета и осложнений, связанных с диабетом. Для этого предлагают вводить препарат из группы усилителей чувствительности к инсулину, исключая троглитазон, в сочетании с препаратом из группы усилителей секреции инсулина, а также выбранном из ингибиторов альфа-глюкозидазы, ингибиторов альфа-редуктазы, бигуанидов, статиновых соединений, ингибиторов синтеза сквалена, фибратных соединений, усилителей катаболизма ЛНП и ингибиторов АПФ. Сочетания этих препаратов вводят также в виде смеси. Указанные сочетания, помимо гипогликемического эффекта, обеспечивают снижение веса, концентрации триглицеридов в плазме крови, неожиданно высокую активность в отношении снижения концентрации глюкозы в крови при сохранении дозы усилителя чувствительности к инсулину. 2 с. и 10 з.п. ф-лы, 5 табл.
Description
Текст описания в факсимильном виде (см. графическую часть)т
Claims (12)
1. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему усилителя чувствительности к инсулину (исключая троглитазон) в сочетании с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма липопротеинов низкой плотности (ЛНП) и ингибитор ангиотензинпревращающего фермента.
2. Способ по п.1, отличающийся тем, что усилитель чувствительности к инсулину представляет собой соединение, формулы
где R представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть соединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть соединены друг с другом с образованием связи,
или его фармакологически приемлемую соль.
3. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой пиоглитазон.
4. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой BRL-49653.
5. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину смешан с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента с образованием смеси и данную смесь вводят млекопитающему.
6. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину (исключая троглитазон) и по меньшей мере один член из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозо-редуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента, не смешивают вместе, а вводят млекопитающему независимо.
7. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему соединения, представленного формулой
где R` представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть объединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть обьединены друг с другом с образованием связи;
при условии, что R' не является бензопиранильной группой, когда m и n = 0, Х представляет собой СН, А представляет собой связь, Q представляет атом серы, R1, L и М представляют собой атом водорода, а кольцо Е не имеет дополнительных заместителей,
или его фармакологически приемлемую соль (исключая троглитазон) в сочетании с усилителем секреции инсулина.
8. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой пиоглитазон.
9. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой BRL-49653.
10. Способ по п.7, отличающийся тем, что усилитель секреции инсулина представляет собой сульфонилмочевину.
11. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина смешивают вместе с образованием смеси и смесь вводят млекопитающему.
12. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина не смешивают вместе, а вводят млекопитающему независимо.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15350095 | 1995-06-20 | ||
JP07-153500 | 1995-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2223760C2 true RU2223760C2 (ru) | 2004-02-20 |
Family
ID=15563926
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111958/63A RU2323004C2 (ru) | 1995-06-20 | 1996-06-19 | Фармацевтическая композиция |
RU2002104459/14K RU2223760C2 (ru) | 1995-06-20 | 1996-06-19 | Способы профилактики и лечения, применение усилителей чувствительности к инсулину |
RU96111958/14K RU2198682C2 (ru) | 1995-06-20 | 1996-06-19 | Фармацевтическая композиция |
RU2002104459/63A RU2327455C2 (ru) | 1995-06-20 | 1996-06-19 | Способы профилактики и лечения, применение усилителей чувствительности к инсулину |
RU2003130978/14A RU2286148C2 (ru) | 1995-06-20 | 2003-10-20 | Способы профилактики и лечения, применение усилителей чувствительности к инсулину |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111958/63A RU2323004C2 (ru) | 1995-06-20 | 1996-06-19 | Фармацевтическая композиция |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111958/14K RU2198682C2 (ru) | 1995-06-20 | 1996-06-19 | Фармацевтическая композиция |
RU2002104459/63A RU2327455C2 (ru) | 1995-06-20 | 1996-06-19 | Способы профилактики и лечения, применение усилителей чувствительности к инсулину |
RU2003130978/14A RU2286148C2 (ru) | 1995-06-20 | 2003-10-20 | Способы профилактики и лечения, применение усилителей чувствительности к инсулину |
Country Status (26)
Country | Link |
---|---|
US (44) | US5952356A (ru) |
EP (6) | EP0749751A3 (ru) |
JP (3) | JP3148973B2 (ru) |
KR (3) | KR970000233A (ru) |
CN (3) | CN1289082C (ru) |
AR (4) | AR005641A1 (ru) |
AT (2) | ATE256463T1 (ru) |
CA (3) | CA2533845C (ru) |
CY (4) | CY2424B1 (ru) |
CZ (2) | CZ291624B6 (ru) |
DE (4) | DE122009000064I1 (ru) |
DK (2) | DK0861666T3 (ru) |
ES (2) | ES2212208T3 (ru) |
FR (1) | FR09C0055I2 (ru) |
HK (2) | HK1010484A1 (ru) |
HU (1) | HUP9601698A3 (ru) |
LU (2) | LU91298I2 (ru) |
MX (1) | MX9602399A (ru) |
MY (1) | MY127530A (ru) |
NL (2) | NL300258I2 (ru) |
NO (5) | NO313226B1 (ru) |
PT (2) | PT1174135E (ru) |
RU (5) | RU2323004C2 (ru) |
SK (2) | SK287351B6 (ru) |
TW (2) | TWI238064B (ru) |
ZA (1) | ZA965190B (ru) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
RU2158607C2 (ru) * | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Лечение артериосклероза и ксантомы |
WO1997005875A2 (en) | 1995-08-10 | 1997-02-20 | Warner-Lambert Company | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
WO1997037688A2 (en) * | 1996-04-05 | 1997-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
DK1175902T3 (da) | 1996-07-15 | 2005-12-19 | Sankyo Co | Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
AU778947B2 (en) * | 1997-06-18 | 2004-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin |
CZ298469B6 (cs) * | 1997-06-18 | 2007-10-10 | Smithkline Beecham Plc | Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus |
AP1600A (en) * | 1997-06-18 | 2006-04-28 | Smithkline Beecham Plc | Combination of a thiazolidinedione and a sulphonylurea for treating diabetes |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
CA2294134A1 (en) * | 1997-06-18 | 1998-12-23 | Stephen Alistair Smith | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
AU783539B2 (en) * | 1997-06-18 | 2005-11-10 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and sulphonylurea |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
GB9715306D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
AU782419B2 (en) * | 1997-07-18 | 2005-07-28 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
CA2306883C (en) * | 1997-10-20 | 2007-11-27 | Dainippon Pharmaceutical Co., Ltd. | Fast-dissolving pharmaceutical composition comprising as-3201 |
AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US7105552B2 (en) * | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US6329403B1 (en) * | 1998-06-30 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for the treatment of diabetes |
JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
ID29352A (id) | 1998-10-29 | 2001-08-23 | Univ Texas | Penggunaan turunan tiazolidindion untuk mencegah kontraksi uterin dalam persalinan prematur atau laktasi |
AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
AP1692A (en) * | 1998-11-12 | 2006-12-12 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
BR9915285A (pt) * | 1998-11-12 | 2001-08-07 | Smithkline Beecham Plc | Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético |
US6958324B2 (en) | 1998-12-02 | 2005-10-25 | Inotek Pharmaceuticals Corporation | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
US6756360B1 (en) | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
JP4799720B2 (ja) * | 1999-01-29 | 2011-10-26 | 武田薬品工業株式会社 | コーティング処理を施した打錠用杵 |
US6787082B1 (en) * | 1999-01-29 | 2004-09-07 | Takeda Chemical Industries, Ltd. | Compressing mallet with coating treatment |
GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
CN1329359C (zh) * | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
JP2000355550A (ja) * | 1999-04-14 | 2000-12-26 | Takeda Chem Ind Ltd | ケトーシス改善剤 |
BR0009934A (pt) * | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Produto farmacêutico |
GB9910693D0 (en) * | 1999-05-07 | 1999-07-07 | Univ Liverpool | A compound for use in medicine |
US6214842B1 (en) * | 1999-05-12 | 2001-04-10 | Michael S. Malamas | Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia |
CA2377246A1 (en) * | 1999-06-18 | 2000-12-28 | Ranjit C. Desai | Arylthiazolidinedione and aryloxazolidinedione derivatives |
EP1849475A1 (en) | 1999-06-21 | 2007-10-31 | Eli Lilly & Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
AU779730B2 (en) * | 1999-06-30 | 2005-02-10 | Amgen, Inc. | Compounds for the modulation of PPARgamma activity |
WO2001000579A1 (en) * | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
AU2005200818B2 (en) * | 1999-09-17 | 2008-07-17 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6878749B2 (en) * | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
JP4719393B2 (ja) * | 1999-10-06 | 2011-07-06 | 敏男 宮田 | カルボニルストレス改善剤 |
AU1133901A (en) * | 1999-10-08 | 2001-04-23 | Novartis Ag | Method of treating metabolic disorders |
US6274622B1 (en) * | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
HU229352B1 (en) | 1999-11-03 | 2013-11-28 | Bristol Myers Squibb Co | Medicament comprising the combination of metformin and glyburide |
MY125516A (en) * | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
US6402771B1 (en) | 1999-12-23 | 2002-06-11 | Guidant Endovascular Solutions | Snare |
US6660021B1 (en) | 1999-12-23 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Intravascular device and system |
US6575997B1 (en) | 1999-12-23 | 2003-06-10 | Endovascular Technologies, Inc. | Embolic basket |
GB9930688D0 (en) * | 1999-12-24 | 2000-02-16 | Smithkline Beecham Plc | Novel method of treatment |
WO2001047509A2 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
US7918820B2 (en) | 1999-12-30 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Device for, and method of, blocking emboli in vessels such as blood arteries |
US6695813B1 (en) | 1999-12-30 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
WO2001052860A2 (en) * | 2000-01-24 | 2001-07-26 | Inotek Corporation | Method and composition for modulating an immune response |
US6540982B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
CA2399463A1 (en) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Combination drug |
EP1295609A4 (en) * | 2000-02-24 | 2004-11-03 | Takeda Chemical Industries Ltd | DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS |
US6461639B2 (en) * | 2000-05-01 | 2002-10-08 | Aeropharm Technology, Inc. | Core formulation |
US6451342B2 (en) * | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6296874B1 (en) * | 2000-05-01 | 2001-10-02 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and abiguanide |
US6610272B1 (en) * | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US6270797B1 (en) * | 2000-05-18 | 2001-08-07 | Usv Limited | Sustained release pharmaceutical composition containing glipizide and method for producing same |
US6939362B2 (en) * | 2001-11-27 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Offset proximal cage for embolic filtering devices |
US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
US6964670B1 (en) | 2000-07-13 | 2005-11-15 | Advanced Cardiovascular Systems, Inc. | Embolic protection guide wire |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
CA2424060A1 (en) * | 2000-10-12 | 2003-03-31 | Nissan Chemical Industries, Ltd. | Preventives and remedies for complications of diabetes |
US6506203B1 (en) | 2000-12-19 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Low profile sheathless embolic protection system |
EP1349531A1 (en) | 2001-01-12 | 2003-10-08 | Sun Pharmaceuticals Industries Ltd. | Spaced drug delivery system |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
EP1236720B1 (en) | 2001-02-28 | 2005-06-15 | Pfizer Products Inc. | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
DE50207110D1 (de) * | 2001-03-02 | 2006-07-20 | Lichtwer Pharma Gmbh | Kombinationspräparat zur behandlung des diabetes mellitus |
KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
ATE348100T1 (de) | 2001-03-30 | 2007-01-15 | Pfizer Prod Inc | Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren. |
CN1499971A (zh) * | 2001-04-03 | 2004-05-26 | ֮����ҩ��ʽ���� | 芳基乙烯磺酰胺衍生物的新用途 |
PT1377276E (pt) * | 2001-04-10 | 2011-12-30 | Sun Pharma Advanced Res Co Ltd | Composição de libertação temporizada por pulso |
SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
JP2002360666A (ja) * | 2001-06-11 | 2002-12-17 | Takeda Chem Ind Ltd | コバルト合金を用いた打錠用杵臼 |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US7338510B2 (en) | 2001-06-29 | 2008-03-04 | Advanced Cardiovascular Systems, Inc. | Variable thickness embolic filtering devices and method of manufacturing the same |
US6599307B1 (en) | 2001-06-29 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Filter device for embolic protection systems |
CA2453784A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | A core formulation |
CA2453775A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
US6638294B1 (en) | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
CA2469228A1 (en) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
DE10200138A1 (de) * | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
TWI327462B (en) * | 2002-01-18 | 2010-07-21 | Sumitomo Chemical Co | Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
US20050142065A1 (en) * | 2002-04-26 | 2005-06-30 | Koki Kato | Screening method |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
JP2005537298A (ja) | 2002-08-02 | 2005-12-08 | ペンウェスト ファーマシューティカルズ カンパニー | メトホルミンの徐放性製剤 |
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
KR20120034211A (ko) | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7252675B2 (en) | 2002-09-30 | 2007-08-07 | Advanced Cardiovascular, Inc. | Embolic filtering devices |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20040088000A1 (en) | 2002-10-31 | 2004-05-06 | Muller Paul F. | Single-wire expandable cages for embolic filtering devices |
DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
IN192749B (ru) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
DE10261067A1 (de) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10302452B4 (de) * | 2003-01-23 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
NZ541749A (en) * | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
US7572910B2 (en) * | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
US8591540B2 (en) | 2003-02-27 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Embolic filtering devices |
WO2004108067A2 (en) * | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
BRPI0409136A (pt) * | 2003-04-09 | 2006-04-25 | Japan Tobacco Inc | composto heteroaromático pentacìclico e uso medicinal do mesmo |
US7820158B2 (en) * | 2003-04-10 | 2010-10-26 | Surmodics, Inc. | Ligand-coupled initiator polymers and methods of use |
US9345671B2 (en) * | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
CA2524175C (en) * | 2003-04-28 | 2016-06-14 | Sankyo Company Limited | Sugar intake-ability enhancer |
US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
JP2007502847A (ja) * | 2003-05-13 | 2007-02-15 | シントン・ベスローテン・フェンノートシャップ | チアゾリジンジオン誘導体およびその化合物を製造する方法 |
US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
BRPI0412009A (pt) * | 2003-06-27 | 2006-08-15 | Reddy Research Foundation | composições compreendendo balaglitazona e outros compostos antidiabéticos |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
EP1651251A4 (en) * | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
CA2543498A1 (en) * | 2003-10-27 | 2005-05-06 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
HUE028576T2 (en) * | 2003-10-31 | 2016-12-28 | Takeda Pharmaceuticals Co | Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester |
US7892251B1 (en) | 2003-11-12 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Component for delivering and locking a medical device to a guide wire |
EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
US7360069B2 (en) * | 2004-01-13 | 2008-04-15 | Hewlett-Packard Development Company, L.P. | Systems and methods for executing across at least one memory barrier employing speculative fills |
EP1555021A1 (en) * | 2004-01-16 | 2005-07-20 | National Health Research Institutes | Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer |
JP4901218B2 (ja) * | 2004-02-09 | 2012-03-21 | あすか製薬株式会社 | 併用医薬 |
EP1716144A2 (en) * | 2004-02-20 | 2006-11-02 | Synthon B.V. | Processes for making pioglitazone and compounds of the processes |
EP1734953A4 (en) * | 2004-03-02 | 2008-08-20 | Abeille Pharmaceuticals Inc | CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS |
US7678129B1 (en) | 2004-03-19 | 2010-03-16 | Advanced Cardiovascular Systems, Inc. | Locking component for an embolic filter assembly |
US7161756B2 (en) * | 2004-05-10 | 2007-01-09 | Tandberg Data Storage Asa | Method and system for communication between a tape drive and an external device |
CN1327840C (zh) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
CN101014360A (zh) * | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素-双胍组合物 |
JP2008514549A (ja) * | 2004-09-14 | 2008-05-08 | エリクシアー ファーマシューティカルズ, インコーポレイテッド | 制御された炭水化物消化のための併用療法 |
MXPA04009236A (es) * | 2004-09-23 | 2006-03-27 | Jorge Luis Rosado Loria | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ppar調節剤およびそのスクリーニング方法 |
US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US9259305B2 (en) | 2005-03-31 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Guide wire locking mechanism for rapid exchange and other catheter systems |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
CN101217965B (zh) * | 2005-07-07 | 2012-07-18 | 学校法人浦项工科大学校 | 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法 |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
CN101227908A (zh) * | 2005-07-22 | 2008-07-23 | 宝洁公司 | 用于减少药源性心律失常发生的组合物 |
MXPA05013220A (es) * | 2005-12-06 | 2007-06-05 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. |
TWI384985B (zh) | 2005-12-22 | 2013-02-11 | Takeda Pharmaceutical | 固體製劑 |
FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
AU2007227581B2 (en) | 2006-03-16 | 2012-11-08 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
CA2647258A1 (en) * | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
WO2007117147A1 (en) * | 2006-04-11 | 2007-10-18 | Sorbwater Technology As | Method for removal of materials from a liquid stream |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
EP2037928B1 (en) | 2006-06-26 | 2012-01-11 | Amgen Inc. | Methods for treating atherosclerosis |
US7752724B2 (en) * | 2006-06-27 | 2010-07-13 | Lumino, Inc. | Method of cutting blinds |
WO2008026668A1 (fr) * | 2006-08-31 | 2008-03-06 | Daiichi Sankyo Company, Limited | Composition médicale contenant un agent d'amélioration de la résistance à l'insuline |
US20080182880A1 (en) * | 2006-09-28 | 2008-07-31 | Mailatur Sivaraman Mohan | Pioglitazone composition |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
US20080176905A1 (en) * | 2007-01-22 | 2008-07-24 | Santiago Ini | Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
PL2106260T3 (pl) | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
BRPI0807453B8 (pt) * | 2007-02-01 | 2021-05-25 | Takeda Pharmaceuticals Co | preparação sólida |
WO2008124122A1 (en) * | 2007-04-09 | 2008-10-16 | Scidose, Llc | Combinations of statins and anti-obesity agent and glitazones |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
AU2008240158B2 (en) | 2007-04-11 | 2014-07-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US7867273B2 (en) | 2007-06-27 | 2011-01-11 | Abbott Laboratories | Endoprostheses for peripheral arteries and other body vessels |
EP2489730B1 (en) | 2007-07-26 | 2015-12-30 | Amgen, Inc | Modified lecithin-cholesterol acyltransferase enzymes |
CN101848901B (zh) * | 2007-09-14 | 2012-11-21 | 新陈代谢解决方案开发公司 | 用于治疗高血压的噻唑烷二酮类似物 |
JPWO2009038107A1 (ja) * | 2007-09-21 | 2011-01-06 | キッセイ薬品工業株式会社 | 2型糖尿病治療用の組合せ医薬 |
US20100311092A1 (en) * | 2007-11-30 | 2010-12-09 | Kurland Irwin J | Metabolic fuel switching biomarker |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
WO2009120844A2 (en) * | 2008-03-26 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US8815508B2 (en) | 2008-08-12 | 2014-08-26 | Zinfandel Pharmaceuticals, Inc. | Method of identifying disease risk factors |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
EP3398599A1 (en) | 2009-03-11 | 2018-11-07 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20110038848A1 (en) * | 2009-08-12 | 2011-02-17 | Melaleuca, Inc. | Dietary supplement compositions for cardiovascular health |
CN102655866B (zh) | 2009-11-13 | 2013-11-13 | 东丽株式会社 | 糖尿病的治疗或预防药 |
US8575177B2 (en) * | 2009-12-04 | 2013-11-05 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
JP2013514368A (ja) * | 2009-12-15 | 2013-04-25 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 神経変性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物 |
ES2658168T3 (es) * | 2009-12-15 | 2018-03-08 | Cirius Therapeutics, Inc. | Sales de tiazolidinadiona ahorradoras de PPAR para el tratamiento de enfermedades metabólicas |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
JP2013523819A (ja) * | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置 |
RU2526153C2 (ru) * | 2010-07-15 | 2014-08-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
EP2611434A1 (en) | 2010-09-01 | 2013-07-10 | Lupin Limited | Pharmaceutical composition comprising metformin and pioglitazone |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
SG191399A1 (en) | 2011-01-10 | 2013-08-30 | Zinfandel Pharmaceuticals Inc | Methods and drug products for treating alzheimer's disease |
HUE026715T2 (en) | 2011-01-20 | 2016-07-28 | Bionevia Pharmaceuticals Inc | Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use |
WO2013034174A1 (en) | 2011-09-06 | 2013-03-14 | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. | Solid preparations of pioglitazone and glimepiride |
DK2771003T3 (en) | 2011-10-28 | 2017-07-17 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease |
CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
RU2572706C1 (ru) * | 2014-06-30 | 2016-01-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
DK3253382T3 (da) | 2015-02-06 | 2022-02-14 | Intercept Pharmaceuticals Inc | Farmaceutiske sammensætninger til kombinationsterapi |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
WO2018130679A1 (en) | 2017-01-16 | 2018-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
EP3807895A1 (en) | 2018-06-14 | 2021-04-21 | AstraZeneca UK Limited | Methods for lowering blood sugar with a metformin pharmaceutical composition |
US20220226350A1 (en) | 2019-05-30 | 2022-07-21 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
CN112869173A (zh) * | 2021-01-18 | 2021-06-01 | 广州富诺营养科技有限公司 | 一种复合维生素矿物质制剂及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5728073A (en) * | 1980-07-29 | 1982-02-15 | Takeda Chem Ind Ltd | Inhibitor for aldose reducing enzyme |
US4863922A (en) * | 1984-12-12 | 1989-09-05 | Merck & Co., Inc. | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
WO1988006887A1 (en) | 1987-03-20 | 1988-09-22 | Alcon Laboratories, Inc. | Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus |
DE3729209A1 (de) * | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
ES2137915T3 (es) | 1987-09-04 | 2000-01-01 | Beecham Group Plc | Derivados de tiazolidindiona sustituida. |
US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
JPH0466579A (ja) * | 1990-07-04 | 1992-03-02 | Yamanouchi Pharmaceut Co Ltd | チアゾリジン誘導体 |
JPH0469383A (ja) * | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
US5260275A (en) * | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2686861B2 (ja) * | 1991-03-30 | 1997-12-08 | キッセイ薬品工業株式会社 | 新規なベンジリデンコハク酸誘導体 |
DK0601001T3 (da) * | 1991-08-26 | 1997-10-20 | Upjohn Co | Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre. |
JPH05202042A (ja) * | 1992-01-24 | 1993-08-10 | Sankyo Co Ltd | 糖尿病性合併症治療剤 |
JPH07316144A (ja) * | 1994-03-29 | 1995-12-05 | Sankyo Co Ltd | ジフェニルメチルピペラジン誘導体 |
TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
US5674900A (en) * | 1995-06-06 | 1997-10-07 | Shaman Pharmaceuticals, Inc. | Terpenoid-type quinones for treatment of diabetes |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
RU2158607C2 (ru) * | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Лечение артериосклероза и ксантомы |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US6001049A (en) * | 1998-02-12 | 1999-12-14 | Frey; Mark P. | Light weight exercise apparatus |
-
1996
- 1996-06-12 TW TW090105054A patent/TWI238064B/zh not_active IP Right Cessation
- 1996-06-12 TW TW085107042A patent/TW438587B/zh not_active IP Right Cessation
- 1996-06-18 SK SK794-96A patent/SK287351B6/sk not_active IP Right Cessation
- 1996-06-18 SK SK1449-2001A patent/SK287287B6/sk not_active IP Right Cessation
- 1996-06-18 JP JP15672596A patent/JP3148973B2/ja not_active Expired - Lifetime
- 1996-06-19 CN CNB021491313A patent/CN1289082C/zh not_active Expired - Fee Related
- 1996-06-19 RU RU96111958/63A patent/RU2323004C2/ru active
- 1996-06-19 AR ARP960103195A patent/AR005641A1/es not_active Application Discontinuation
- 1996-06-19 RU RU2002104459/14K patent/RU2223760C2/ru active IP Right Maintenance
- 1996-06-19 MX MX9602399A patent/MX9602399A/es active IP Right Grant
- 1996-06-19 CN CNA021491321A patent/CN1530106A/zh active Pending
- 1996-06-19 CN CNB961110635A patent/CN1212117C/zh not_active Expired - Lifetime
- 1996-06-19 CZ CZ19961811A patent/CZ291624B6/cs not_active IP Right Cessation
- 1996-06-19 NO NO19962606A patent/NO313226B1/no not_active IP Right Cessation
- 1996-06-19 ZA ZA9605190A patent/ZA965190B/xx unknown
- 1996-06-19 RU RU96111958/14K patent/RU2198682C2/ru active IP Right Maintenance
- 1996-06-19 US US08/667,979 patent/US5952356A/en not_active Expired - Lifetime
- 1996-06-19 RU RU2002104459/63A patent/RU2327455C2/ru active
- 1996-06-20 MY MYPI96002486A patent/MY127530A/en unknown
- 1996-06-20 HU HU9601698A patent/HUP9601698A3/hu not_active Application Discontinuation
- 1996-06-20 AT AT98200252T patent/ATE256463T1/de active
- 1996-06-20 CA CA2533845A patent/CA2533845C/en not_active Expired - Fee Related
- 1996-06-20 DE DE200912000064 patent/DE122009000064I1/de active Pending
- 1996-06-20 CA CA002179584A patent/CA2179584C/en not_active Expired - Lifetime
- 1996-06-20 EP EP96304570A patent/EP0749751A3/en not_active Ceased
- 1996-06-20 PT PT01203170T patent/PT1174135E/pt unknown
- 1996-06-20 DK DK98200252T patent/DK0861666T3/da active
- 1996-06-20 KR KR1019960022615A patent/KR970000233A/ko not_active Application Discontinuation
- 1996-06-20 EP EP98200252A patent/EP0861666B1/en not_active Revoked
- 1996-06-20 CA CA002531834A patent/CA2531834C/en not_active Expired - Lifetime
- 1996-06-20 PT PT98200252T patent/PT861666E/pt unknown
- 1996-06-20 EP EP01203170.4A patent/EP1174135B2/en not_active Expired - Lifetime
- 1996-06-20 ES ES98200252T patent/ES2212208T3/es not_active Expired - Lifetime
- 1996-06-20 DE DE69637988T patent/DE69637988D1/de not_active Expired - Lifetime
- 1996-06-20 EP EP10012500A patent/EP2292268A1/en not_active Withdrawn
- 1996-06-20 AT AT01203170T patent/ATE438397T1/de active
- 1996-06-20 DE DE69631157T patent/DE69631157T2/de not_active Expired - Lifetime
- 1996-06-20 EP EP10012501A patent/EP2289556A3/en not_active Withdrawn
- 1996-06-20 EP EP06022352A patent/EP1764110A1/en not_active Withdrawn
- 1996-06-20 DK DK01203170T patent/DK1174135T3/da active
- 1996-06-20 ES ES01203170.4T patent/ES2327383T5/es not_active Expired - Lifetime
-
1997
- 1997-12-26 JP JP36075697A patent/JP3973280B2/ja not_active Expired - Lifetime
-
1998
- 1998-04-09 US US09/057,465 patent/US5965584A/en not_active Expired - Lifetime
- 1998-10-22 HK HK98111476A patent/HK1010484A1/xx not_active IP Right Cessation
-
1999
- 1999-03-30 US US09/280,710 patent/US6150383A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,494 patent/US6172089B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,493 patent/US6150384A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,492 patent/US6166043A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,495 patent/US6172090B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,469 patent/US6133293A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,508 patent/US6214848B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,468 patent/US6169099B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,497 patent/US6156773A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,470 patent/US6166042A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,496 patent/US6121295A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,097 patent/US6225326B1/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,099 patent/US6133295A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,098 patent/US6080765A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,096 patent/US6121294A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,095 patent/US6174904B1/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,504 patent/US6169100B1/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,457 patent/US6103742A/en not_active Expired - Lifetime
- 1999-12-03 US US09/453,521 patent/US6329404B1/en not_active Expired - Lifetime
-
2000
- 2000-06-29 US US09/606,176 patent/US6211205B1/en not_active Expired - Lifetime
- 2000-06-29 US US09/605,704 patent/US6303640B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,993 patent/US6232330B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,992 patent/US6288090B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,994 patent/US6218409B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,635 patent/US6251924B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,636 patent/US6239153B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,634 patent/US6323225B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,641 patent/US6211207B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,640 patent/US6211206B1/en not_active Expired - Lifetime
- 2000-09-01 NO NO20004345A patent/NO314065B1/no not_active IP Right Cessation
- 2000-11-28 US US09/722,330 patent/US6274605B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,597 patent/US6271243B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,291 patent/US6277869B1/en not_active Expired - Lifetime
-
2001
- 2001-07-19 US US09/907,768 patent/US20020002186A1/en not_active Abandoned
- 2001-10-11 US US09/973,689 patent/US6384062B1/en not_active Expired - Lifetime
-
2002
- 2002-02-21 HK HK02101272.5A patent/HK1041203B/zh not_active IP Right Cessation
- 2002-02-28 US US10/084,479 patent/US20020123512A1/en not_active Abandoned
- 2002-03-08 NO NONO/SPC/2A patent/NO317341B1/no not_active IP Right Cessation
- 2002-03-13 US US10/095,453 patent/US6599923B2/en not_active Expired - Lifetime
- 2002-07-15 CZ CZ20022453A patent/CZ292093B6/cs not_active IP Right Cessation
-
2003
- 2003-06-17 US US10/462,793 patent/US6911459B2/en not_active Expired - Fee Related
- 2003-10-20 RU RU2003130978/14A patent/RU2286148C2/ru not_active IP Right Cessation
-
2004
- 2004-02-19 CY CY0400010A patent/CY2424B1/xx unknown
- 2004-07-26 US US10/898,316 patent/US20040266830A1/en not_active Abandoned
- 2004-09-10 US US10/937,494 patent/US7144900B2/en not_active Expired - Fee Related
- 2004-10-07 KR KR1020040079966A patent/KR20070081135A/ko not_active Application Discontinuation
-
2006
- 2006-09-20 US US11/523,771 patent/US7538125B2/en not_active Expired - Fee Related
- 2006-12-20 LU LU91298C patent/LU91298I2/fr unknown
-
2007
- 2007-01-04 NO NO2007001C patent/NO2007001I2/no unknown
- 2007-01-08 CY CY200700001C patent/CY2007001I2/el unknown
- 2007-01-08 DE DE200712000002 patent/DE122007000002I2/de active Active
- 2007-01-25 NL NL300258C patent/NL300258I2/nl unknown
- 2007-04-25 JP JP2007115861A patent/JP4809806B2/ja not_active Expired - Lifetime
- 2007-05-28 AR ARP070102280A patent/AR061195A2/es not_active Application Discontinuation
- 2007-06-04 NO NO2007007C patent/NO2007007I2/no unknown
- 2007-12-20 KR KR1020070134272A patent/KR20080005162A/ko not_active Application Discontinuation
-
2008
- 2008-02-20 AR ARP080100677A patent/AR065389A2/es not_active Application Discontinuation
-
2009
- 2009-03-20 US US12/382,691 patent/US7842706B2/en not_active Expired - Fee Related
- 2009-09-09 LU LU91606C patent/LU91606I2/fr unknown
- 2009-10-20 CY CY0900011A patent/CY2608B2/xx unknown
- 2009-10-23 FR FR09C0055C patent/FR09C0055I2/fr active Active
- 2009-12-01 CY CY2009018C patent/CY2009018I2/el unknown
-
2010
- 2010-01-15 NL NL300432C patent/NL300432I2/en unknown
- 2010-10-19 US US12/923,975 patent/US20110034518A1/en not_active Abandoned
-
2011
- 2011-01-06 AR ARP110100033 patent/AR091289A2/es not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
LEFEVRE et al. Drugs. - 1992, 44, р.29-38. * |
Клиническая эндокринология. Руководство для врачей/Под ред. Н.Т. Старковой. - М.: Медицина, 1991, с.236-239, 254-256. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2223760C2 (ru) | Способы профилактики и лечения, применение усилителей чувствительности к инсулину | |
RU2002104459A (ru) | Способы профилактики и лечения, применение усилителей чувствительности к инсулину | |
RU96111958A (ru) | Фармацевтическая композиция | |
CA1331020C (en) | Medicament with improved penetration of the tissue membrane | |
RU2227800C2 (ru) | Новые эффекторы дипептидилпептидазы iv | |
JP4875491B2 (ja) | メトホルミンとスタチンとの組み合わせを含む医薬組成物 | |
AU2006222060B2 (en) | Roflumilast for the treatment of diabetes mellitus | |
RU2001118826A (ru) | N-замещенные 2-цианопирролидины | |
RU95118725A (ru) | Производные оксазолидиндиона, их получение и фармацевтическая композиция | |
RU2006143666A (ru) | Фармацевтические композиции в виде раствора, содержащие 17-aag | |
RU2009102515A (ru) | Конденсированные циклические соединения | |
CN1186495A (zh) | 降低活体内氧化氮水平的方法及其可用的组合物 | |
CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
JP2007528886A (ja) | 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用 | |
RU2004109586A (ru) | Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов | |
CA2377661A1 (en) | Use of fatty acid derivative for the treatment of external secretion disorders | |
DE69405425D1 (de) | Oxazolidinedione-Derivate, ihre Herstellung und ihre Verwendung zur Hemmung Zucker und Lipid in Blut | |
WO2018148206A1 (en) | Treatment of diabetes and associated metabolic conditions with epigenetic modulators | |
AU601326B2 (en) | 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function | |
BR0311834A (pt) | Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável | |
AU637745B2 (en) | Use of tenidap to inhibit the activity of myeloperoxidase | |
CA2445651A1 (en) | Cathartic composition comprising halogenated prostaglandin derivatives | |
CA1313139C (en) | D1-5-[(2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2,4-dione as an anti-atherosclerosis agent | |
NZ312571A (en) | Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein | |
EP0132994A1 (en) | Compounds for lowering lipid levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
MF42 | Invention patent partially invalidated |
Effective date: 20071205 |